Agency recommends second dose of Janssen for adults
The European Medicines Agency (EMA) has recommended boosting the Janssen vaccine for covid-19 in adults at least two months after the first dose.
According to a statement from the EMA, the recommendation is based on "data showing that a booster dose of Janssen Vaccine [by Johnson & Johnson], given at least two months after the first dose in adults, led to an increase in antibodies" against the virus that causes the disease.
According to the agency, "the risk of thrombosis in combination with thrombocytopenia or other side effects, very rare after a booster, is not known and is being carefully monitored."
The EMA indicates that Janssen's covid-19 vaccine can be administered after two doses of one of the vaccines developed with mRNA technology authorized in the European Union: Cominarty, from Pfizer/BioNTech, or Spikevax, from Moderna.
Covid-19 has caused at least 5.311 million deaths worldwide, among more than 269 million infections with the new coronavirus recorded since the start of the pandemic, according to the latest report by the Agence France-Presse.
The respiratory disease is caused by the SARS-CoV-2 coronavirus, detected at the end of 2019 in Wuhan, a city in central China, and currently with variants identified in several countries.
A new variant, Ômicron, classified as "worrying" by the World Health Organization (WHO), has been detected in southern Africa, but since the South African health authorities issued the warning on November 24, infections in the skin have been reported. minus 57 countries from all continents.
Text translated using artificial intelligence.
